Research
Hormonal
GLP-1 receptor agonists (liraglutide, semaglutide) reduce major adverse cardiovascular events (MACE) and nephropathy progression in high-risk patients with Type 2 Diabetes.
For those with Type 2 Diabetes and high heart risk, GLP-1 agonists like liraglutide or semaglutide offer strong protection against heart attacks and strokes, as well as kidney damage. Discuss these options with your doctor, especially if you are overweight.
StrongSupportsVERY_HIGH confidence
The Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) trial... observed a 13% reduction in major adverse cardiovascular events (MACE) and a significant reduction in nephropathy progression... The Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes Outcome Study 6 (SUSTAIN-6) trial... demonstrated a 26% reduction in MACE.
Why this rating
Based on large-scale randomized controlled trials (LEADER, SUSTAIN-6).
Source
Cardio-Renal Metabolic Syndrome: An Integrated Approach to Prevention and Management
Adeshpal Singh et al. · Cureus · 2025
DOI 10.7759/cureus.94134
narrative_review
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- SGLT2 inhibitors (empagliflozin, dapagliflozin) reduce cardiovascular death, heart failure hospitalizations, and renal composite outcomes in patients with type 2 diabetes and chronic kidney disease, regardless of baseline glycemic control.Strong
- Lifestyle interventions (diet, exercise, weight loss, smoking cessation) significantly reduce the risk of developing Type 2 Diabetes, cardiovascular disease, and chronic kidney disease progression.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →